Most linked-to pages

Showing below up to 50 results in range #101 to #150.

101. Comparable to standard treatment, specifics depend on individual patient factors.‏‎ (2 links)
102. Data varies; traditional radiation therapies offer median OS of around 16-21 months for glioblastoma‏‎ (2 links)
103. Dendritic Cell Vaccine (DCVax-L)‏‎ (2 links)
104. Disulfiram‏‎ (2 links)
105. Early studies indicate variable results; ongoing trials, including combinations with PARP inhibitors, aim to determine efficacy‏‎ (2 links)
106. Early trials show median survival times from 56 weeks for recurrent GBM to up to 24.9 months in certain cohorts‏‎ (2 links)
107. Enhancements in progression-free survival noted in combination therapies, ranging from improvement in median progression-free survival times to higher 6-month survival rates‏‎ (2 links)
108. Gamma Knife Radiosurgery‏‎ (2 links)
109. Gleevec (Imatinib)‏‎ (2 links)
110. High-dose PBT showed a median OS of 65.6 months for patients with radiation necrosis, and 26.9 months for patients without radiation necrosis in specific studies‏‎ (2 links)
111. Historical mOS for similar patient population using lomustine is 7.2 months‏‎ (2 links)
112. Hyperthermia‏‎ (2 links)
113. ICT-107‏‎ (2 links)
114. ICT-107 (Tumor-associated Antigen Vaccine)‏‎ (2 links)
115. Improved PFS observed with PBT, specific rates vary by study‏‎ (2 links)
116. Increases observed in specific combination trials, such as Irinotecan with Bevacizumab‏‎ (2 links)
117. Letrozole‏‎ (2 links)
118. Lower compared to traditional GBM treatments, with no significant radiation-induced toxicities reported in recent studies.‏‎ (2 links)
119. MDNA55‏‎ (2 links)
120. MN-166‏‎ (2 links)
121. Median overall survival for GBM typically ranges around 16 months with standard treatment.‏‎ (2 links)
122. Median progression-free survival with standard treatments is about 6-9 months for GBM‏‎ (2 links)
123. Metformin‏‎ (2 links)
124. Methadone‏‎ (2 links)
125. Metronomic Low-Dose Temozolomide (TMZ)‏‎ (2 links)
126. Metronomic low dose temozolomide (TMZ)‏‎ (2 links)
127. Next-Generation CAR T-Cell Therapy for GBM‏‎ (2 links)
128. Not directly specified; historical control data needed for comprehensive comparison‏‎ (2 links)
129. Not directly specified; ongoing studies aim to clarify Carboplatin's impact on survival in recurrent glioma‏‎ (2 links)
130. Not fully established from available data‏‎ (2 links)
131. Not specified; however, survival six months after recurrence was used as a primary measure in comparative studies with Avastin‏‎ (2 links)
132. Not specified in the provided context‏‎ (2 links)
133. Optune‏‎ (2 links)
134. Optune (Optune Gio® for newer version)‏‎ (2 links)
135. Over-the-Counter Drugs and Supplements‏‎ (2 links)
136. Pending further clinical trials‏‎ (2 links)
137. Pending further clinical trials and data‏‎ (2 links)
138. Pending review of recent clinical trials and comparative studies‏‎ (2 links)
139. Phase II trial showed a significant improvement in PFS, particularly for HLA-A2 positive patients with methylated MGMT, showing a median PFS of 24.1 months vs. 8.5 months in the control group.‏‎ (2 links)
140. Platinum Compounds‏‎ (2 links)
141. Proton Pump Inhibitors‏‎ (2 links)
142. Radiation dermatitis, temporary alopecia, radiation otitis, radiation necrosis (more prevalent in PBT group)‏‎ (2 links)
143. Radiation via Monoclonal Antibodies‏‎ (2 links)
144. Ranges from 26 to 44% with different schedules; 61% PFS-6 with the best results obtained using a specific dosing schedule‏‎ (2 links)
145. SL-701‏‎ (2 links)
146. SL-701 (Immunotherapy Vaccine)‏‎ (2 links)
147. Some studies report mean progression-free survival up to 17.2 months, compared to 4-10 months for other treatments‏‎ (2 links)
148. Standard radiation therapy PFS rates are lower compared to PBT‏‎ (2 links)
149. Standard treatments for GBM typically result in a median overall survival of 14-17 months‏‎ (2 links)
150. Standard treatments offer a median progression-free survival of about 6.9 months.‏‎ (2 links)